tetano
Editor, Senior Moderator
Cell Death Differ
. 2021 Aug 17.
doi: 10.1038/s41418-021-00844-6. Online ahead of print.
Repurposing the estrogen receptor modulator raloxifene to treat SARS-CoV-2 infection
Marcello Allegretti[SUP] 1 [/SUP], Maria Candida Cesta[SUP] 2 [/SUP], Mara Zippoli[SUP] 2 [/SUP], Andrea Beccari[SUP] 2 [/SUP], Carmine Talarico[SUP] 2 [/SUP], Flavio Mantelli[SUP] 2 [/SUP], Enrico M Bucci[SUP] 3 [/SUP], Laura Scorzolini[SUP] 4 [/SUP], Emanuele Nicastri[SUP] 4 [/SUP]
Affiliations
Abstract
The ongoing coronavirus disease 2019 (COVID-19) pandemic caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) necessitates strategies to identify prophylactic and therapeutic drug candidates to enter rapid clinical development. This is particularly true, given the uncertainty about the endurance of the immune memory induced by both previous infections or vaccines, and given the fact that the eradication of SARS-CoV-2 might be challenging to reach, given the attack rate of the virus, which would require unusually high protection by a vaccine. Here, we show how raloxifene, a selective estrogen receptor modulator with anti-inflammatory and antiviral properties, emerges as an attractive candidate entering clinical trials to test its efficacy in early-stage treatment COVID-19 patients.
. 2021 Aug 17.
doi: 10.1038/s41418-021-00844-6. Online ahead of print.
Repurposing the estrogen receptor modulator raloxifene to treat SARS-CoV-2 infection
Marcello Allegretti[SUP] 1 [/SUP], Maria Candida Cesta[SUP] 2 [/SUP], Mara Zippoli[SUP] 2 [/SUP], Andrea Beccari[SUP] 2 [/SUP], Carmine Talarico[SUP] 2 [/SUP], Flavio Mantelli[SUP] 2 [/SUP], Enrico M Bucci[SUP] 3 [/SUP], Laura Scorzolini[SUP] 4 [/SUP], Emanuele Nicastri[SUP] 4 [/SUP]
Affiliations
- PMID: 34404919
- DOI: 10.1038/s41418-021-00844-6
Abstract
The ongoing coronavirus disease 2019 (COVID-19) pandemic caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) necessitates strategies to identify prophylactic and therapeutic drug candidates to enter rapid clinical development. This is particularly true, given the uncertainty about the endurance of the immune memory induced by both previous infections or vaccines, and given the fact that the eradication of SARS-CoV-2 might be challenging to reach, given the attack rate of the virus, which would require unusually high protection by a vaccine. Here, we show how raloxifene, a selective estrogen receptor modulator with anti-inflammatory and antiviral properties, emerges as an attractive candidate entering clinical trials to test its efficacy in early-stage treatment COVID-19 patients.